HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perrigo divests Israel consumer biz

This article was originally published in The Rose Sheet

Executive Summary

Allegan, Mich.-based Perrigo Company signed an agreement to sell its Israel Consumer Products business and related production assets to Emilia Group, a subsidiary of O. Feller Holdings Ltd., for approximately $54 mil. The transaction will close in the first quarter of 2010, the firm says. The divestment "execut[es] our previously announced decision to exit this business," Perrigo Chairman and CEO Joseph C. Papa said in a statement. Perrigo will provide distribution and support services for the related U.S. private label cosmetics business for 12 months after the close of the transaction, release states

You may also be interested in...



Perrigo Will Acquire Orion Labs To Reach Australian Market

Perrigo's pending $49 million acquisition of Orion Laboratories marks the private labeler's entrance into the promising Australian OTC market and adds a "beachhead" for the firm's continued global expansion, analysts say

Perrigo Will Acquire Orion Labs To Reach Australian Market

Perrigo's pending $49 million acquisition of Orion Laboratories marks the private labeler's entrance into the promising Australian OTC market and adds a "beachhead" for the firm's continued global expansion, analysts say

Novel Brain Penetrant For Treating X-ALD Among Raft Of New EU Filings

Investigational products from Minoryx and a host of other companies targeting a range of diseases are now under review by the European Medicines Agency for potential EU approval.

Latest News
See All
UsernamePublicRestriction

Register

RS016534

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel